Warning against a non-negotiated exit from the EU in the midst of the COVID-19 pandemic, Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, has cautioned that a “no-deal” Brexit could “potentially disrupt supplies of medicines further at the end of the year.”
Currently, the UK is due to end its transition period with the EU on 31 December 2020 after formally leaving the EU in January
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?